Sermorelin vs Tesamorelin: Which Growth-Hormone Peptide Fits Your Goals

If your goal matches tesamorelin's approval, meaning excess abdominal fat in an adult living with HIV and lipodystrophy, tesamorelin is the evidence-backed choice. It has two randomized, placebo-controlled trials behind it and an FDA label that spells out exactly who it is for.

If you are an adult looking for clinician-guided support for recovery, sleep or body composition outside that diagnosis, tesamorelin is not approved for you, and sermorelin is the more practical conversation. It is prescribed as a compounded medication, it is not FDA-approved, and the evidence in healthy adults is limited. The program is built to support your own growth-hormone signaling with a clinician watching your response, not to deliver a guaranteed result.

Everything below is the detail behind those two paragraphs.

Both peptides imitate growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary gland. Neither one is growth hormone. Each prompts the pituitary to make and release its own, in the natural pulsing pattern the body already uses, which the tesamorelin label describes directly (Egrifta WR label).

Tesamorelin: the full sequence, modified

Tesamorelin contains the full 44 amino acid sequence of human GHRH with a small chemical group added to one end. The label reports it binds human GHRH receptors with potency similar to the body's own hormone.

Sermorelin: the active fragment

Sermorelin is a 29 amino acid analogue of GHRH, described in a published review as the shortest synthetic peptide with the full biological activity of GHRH (Prakash and Goa, 1999). Because the pituitary stays in the loop, your body keeps regulating the release rhythm, which is how Harbor describes it in our sermorelin explainer.

Why timing comes up

Both peptides act briefly. The tesamorelin label reports a half-life of about 11 minutes after an injection, so the effect comes from the growth-hormone pulse it triggers rather than from the drug lingering. In the pediatric sermorelin studies, the once-daily dose was given at bedtime (Prakash and Goa, 1999), which lines up with the body's own growth-hormone release, most of which is tied to deep slow-wave sleep (Van Cauter and Copinschi, 2000). That is why timing is part of the conversation for both.

So the mechanism is shared. What separates the two is what each has been approved for and tested in.

Tesamorelin: two randomized trials, one population

The label is built on two 26-week, placebo-controlled trials in adults with HIV, lipodystrophy and excess abdominal fat. Visceral fat measured by CT fell 18% on tesamorelin versus a 2% rise on placebo in the first study, and 14% versus 2% in the second. Body weight barely moved, which is why the label says tesamorelin is not indicated for weight loss.

The label also reports what happened to IGF-1, the growth factor the liver makes in response to growth hormone. In the first study it rose by about 107 ng/mL on tesamorelin while falling slightly on placebo, which is the signal the drug is doing what a GHRH analog should. The label adds that the effects of a prolonged rise in IGF-1 are unknown, which is why it asks prescribers to monitor it.

Those results apply to that population. The trials excluded people with diabetes, and the label notes there is no information in adults over 65.

Sermorelin: an approved history, thinner adult data

Sermorelin was FDA-approved as Geref, first as a diagnostic test in 1990 and later to treat children with idiopathic growth hormone deficiency. The manufacturer discontinued it in 2008, and the FDA later determined it was not withdrawn for reasons of safety or effectiveness (Federal Register, 2013).

In adults, the evidence is much thinner. Much of the case for adult use rests on smaller studies and commentary rather than large controlled trials (Walker, 2006). Individual responses vary, and a clinician sets expectations based on your history.

That gap matters more than the mechanism does. Two peptides can share a pathway and still differ in how well their effects are understood.

Scroll the table sideways to see both columns →

Both are small subcutaneous injections, and both can cause injection-site redness, itching or soreness. Beyond that, tesamorelin carries more label warnings, partly because it has been studied more formally.

Tesamorelin

The label lists joint pain, injection-site redness and itching, pain in the extremities, swelling and muscle aches as the most common reactions. It also warns about raised IGF-1, fluid retention, and glucose intolerance or diabetes, and recommends checking IGF-1 and glucose during treatment. It is contraindicated in pregnancy, active cancer, and conditions that disrupt the hypothalamic-pituitary axis.

Sermorelin

In the published pediatric data, transient facial flushing and injection-site pain were the most commonly reported effects (Prakash and Goa, 1999). Some people also notice headache or nausea early on, as Harbor's explainer notes.

If you have diabetes or prediabetes, tell your clinician before starting either peptide. Growth hormone affects how the body handles glucose, which is exactly why the tesamorelin label asks prescribers to evaluate glucose before and during treatment.

Tesamorelin is a brand-name prescription with an FDA label, which also means prescribing it outside HIV-associated lipodystrophy is off-label. Coverage and price depend on your plan and on whether your situation matches the approved use.

Sermorelin today is prepared by licensed compounding pharmacies for individual patients. Compounded medications are not reviewed by the FDA for safety or effectiveness (FDA compounding Q&A). At Harbor, a board-certified physician reviews your intake before anything ships, and if it is not the right fit, it is not prescribed. The program starts from $99 a month.

What to ask any clinic offering either one

• Is a licensed physician reviewing your full health history before prescribing, including diabetes, cancer history and pregnancy plans?
• Which licensed pharmacy prepares the medication, and is it dispensed for you specifically on a prescription?
• Who sets and adjusts the dose, and how will they check how you are responding?
• What happens if it turns out not to be a good fit, and can you reach a clinician when you have a question?

A program that sells either peptide without a prescription, or without a clinician you can reach, is a red flag regardless of which one it is.

Tesamorelin is the conversation when

• You are an adult with HIV and lipodystrophy and excess abdominal fat, the population its trials studied
• You want a treatment with an FDA label and formal trial data for your specific situation
• Your HIV care team can prescribe and monitor it alongside your antiretroviral therapy

Sermorelin is the conversation when

• You are a generally healthy adult interested in clinician-guided support for recovery, sleep or body composition
• You understand the adult evidence is limited and want a clinician setting expectations and checking in
• You want a simple at-home routine with physician review, and you are comfortable with a compounded medication

Neither peptide is for everyone. A physician reviews your goals and full health history, including diabetes, cancer history and pregnancy plans, before deciding whether any growth-hormone-releasing peptide is appropriate.